Product Description
Mechanisms of Action: DDR1 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Incendia Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
PRTH-101-0001 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
2027-09-30 |